Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

TBC update: personalized epigenetic management of diabetes.

Fodor A, Cozma A, Karnieli E.

Per Med. 2017 Nov;14(6):531-549. doi: 10.2217/pme-2017-0043. Epub 2017 Nov 24. Review.

PMID:
29749858
2.

Challenges of implementing personalized (precision) medicine: a focus on diabetes.

Fodor A, Karnieli E.

Per Med. 2016 Sep;13(5):485-497. doi: 10.2217/pme-2016-0022. Epub 2016 Jul 27.

PMID:
29767596
3.

Up Close and Personalized: advancing personalized medicine in the 21st century.

Fodor A, Rishe N, Karnieli E.

Per Med. 2015 Nov;12(6):541-543. doi: 10.2217/pme.15.29. Epub 2015 Nov 6. No abstract available.

4.

Personalized epigenetic management of diabetes.

Fodor A, Cozma A, Karnieli E.

Per Med. 2015 Sep;12(5):497-514. doi: 10.2217/pme.15.17. Epub 2015 Sep 3.

PMID:
29749893
5.

Depressive symptoms prior to and following insulin initiation in patients with type 2 diabetes mellitus: Prevalence, risk factors and effect on physician resource utilisation.

Dzida G, Karnieli E, Svendsen AL, Sølje KS, Hermanns N; SOLVE Study Group.

Prim Care Diabetes. 2015 Oct;9(5):346-53. doi: 10.1016/j.pcd.2015.01.002. Epub 2015 Jan 30.

6.

PPARγ gene expression is autoregulated in primary adipocytes: ligand, sumoylation, and isoform specificity.

Armoni M, Harel C, Karnieli E.

Horm Metab Res. 2015 Feb;47(2):89-96. doi: 10.1055/s-0034-1394463. Epub 2014 Nov 19.

PMID:
25409419
7.

AHNAK KO mice are protected from diet-induced obesity but are glucose intolerant.

Ramdas M, Harel C, Armoni M, Karnieli E.

Horm Metab Res. 2015 Apr;47(4):265-72. doi: 10.1055/s-0034-1387736. Epub 2014 Aug 25.

PMID:
25153686
8.

CYP2E1 impairs GLUT4 gene expression and function: NRF2 as a possible mediator.

Armoni M, Harel C, Ramdas M, Karnieli E.

Horm Metab Res. 2014 Jun;46(7):477-83. doi: 10.1055/s-0033-1363990. Epub 2014 Feb 5.

PMID:
24500986
9.

Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study.

Yale JF, Damci T, Kaiser M, Karnieli E, Khunti K, Liebl A, Baeres FM, Svendsen AL, Ross SA; SOLVE Study Group.

Diabetol Metab Syndr. 2013 Oct 2;5(1):56. doi: 10.1186/1758-5996-5-56.

10.

Introduction to personalized medicine in diabetes mellitus.

Glauber HS, Rishe N, Karnieli E.

Rambam Maimonides Med J. 2014 Jan 21;5(1):e0002. doi: 10.5041/RMMJ.10136. eCollection 2014 Jan.

11.

Preventing type 2 diabetes mellitus: a call for personalized intervention.

Glauber H, Karnieli E.

Perm J. 2013 Summer;17(3):74-9. doi: 10.7812/TPP/12-143. Review.

12.

Overcoming barriers in the implementation of personalized medicine into clinical practice.

Cohen MJ, Ginsburg GS, Abrahams E, Bitterman H, Karnieli E.

Isr Med Assoc J. 2013 Oct;15(10):599-601. No abstract available.

13.

Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE).

Karnieli E, Baeres FM, Dzida G, Ji Q, Ligthelm R, Ross S, Svendsen AL, Yale JF; SOLVE Study Group.

Drugs Aging. 2013 Mar;30(3):167-75. doi: 10.1007/s40266-013-0054-3.

14.

Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice.

Caputo S, Andersen H, Kaiser M, Karnieli E, Meneghini LF, Svendsen AL; SOLVE Study Group.

Endocr Pract. 2013 May-Jun;19(3):462-70. doi: 10.4158/EP12269.OR.

PMID:
23337147
15.

The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.

Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Meneghini LF; SOLVE Study Group.

Diabetes Obes Metab. 2012 Dec;14(12):1129-36. doi: 10.1111/j.1463-1326.2012.01665.x. Epub 2012 Aug 30.

PMID:
22830956
16.

Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance.

Zong H, Armoni M, Harel C, Karnieli E, Pessin JE.

Am J Physiol Endocrinol Metab. 2012 Mar 1;302(5):E532-9. doi: 10.1152/ajpendo.00258.2011. Epub 2011 Dec 20.

17.

The metabolic syndrome--from insulin resistance to obesity and diabetes.

Gallagher EJ, Leroith D, Karnieli E.

Med Clin North Am. 2011 Sep;95(5):855-73. doi: 10.1016/j.mcna.2011.06.001. Review.

PMID:
21855696
18.

Obesity.

Leroith D, Karnieli E.

Med Clin North Am. 2011 Sep;95(5):xiii-xv. doi: 10.1016/j.mcna.2011.06.011. No abstract available.

PMID:
21855695
19.

Metabolic profiling in personalized medicine: bridging the gap between knowledge and clinical practice in Type 2 diabetes.

Zolotov S, Ben Yosef D, Rishe ND, Yesha Y, Karnieli E.

Per Med. 2011 Jul;8(4):445-456. doi: 10.2217/pme.11.36.

PMID:
29783337
20.

Insulin resistance in obesity as the underlying cause for the metabolic syndrome.

Gallagher EJ, Leroith D, Karnieli E.

Mt Sinai J Med. 2010 Sep-Oct;77(5):511-23. doi: 10.1002/msj.20212. Review.

PMID:
20960553
21.

GLUT4 in murine bone growth: from uptake and translocation to proliferation and differentiation.

Maor G, Vasiliver-Shamis G, Hazan-Brill R, Wertheimer E, Karnieli E.

Am J Physiol Endocrinol Metab. 2011 Apr;300(4):E613-23. doi: 10.1152/ajpendo.90484.2008. Epub 2010 Oct 5.

22.

Using multi-perspective methodologies to study users' interactions with the prototype front end of a guideline-based decision support system for diabetic foot care.

Peleg M, Shachak A, Wang D, Karnieli E.

Int J Med Inform. 2009 Jul;78(7):482-93. doi: 10.1016/j.ijmedinf.2009.02.008. Epub 2009 Mar 27.

PMID:
19328739
23.

Improvement in glycemic control by gastric electrical stimulation (TANTALUS) in overweight subjects with type 2 diabetes.

Bohdjalian A, Ludvik B, Guerci B, Bresler L, Renard E, Nocca D, Karnieli E, Assalia A, Prager R, Prager G.

Surg Endosc. 2009 Sep;23(9):1955-60. doi: 10.1007/s00464-008-0222-4. Epub 2008 Dec 6.

PMID:
19067068
24.

Preface. "Call to action" in fighting obesity.

Karnieli E.

Endocrinol Metab Clin North Am. 2008 Dec;37(4):xiii. doi: 10.1016/j.ecl.2008.10.001. No abstract available.

PMID:
19026932
25.

Lessons learned from adapting a generic narrative diabetic-foot guideline to an institutional decision-support system.

Peleg M, Wang D, Fodor A, Keren S, Karnieli E.

Stud Health Technol Inform. 2008;139:243-52.

PMID:
18806333
26.

The metabolic syndrome--from insulin resistance to obesity and diabetes.

Gallagher EJ, LeRoith D, Karnieli E.

Endocrinol Metab Clin North Am. 2008 Sep;37(3):559-79, vii. doi: 10.1016/j.ecl.2008.05.002. Review.

PMID:
18775352
27.

The growing prevalence of obesity worldwide is an increasing concern. Preface.

Karnieli E.

Endocrinol Metab Clin North Am. 2008 Sep;37(3):xvii-xviii. doi: 10.1016/j.ecl.2008.07.005. No abstract available.

PMID:
18775351
28.

Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology.

Karnieli E, Armoni M.

Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E38-45. doi: 10.1152/ajpendo.90306.2008. Epub 2008 May 20.

29.

The proposed terminology 'A(1c)-derived average glucose' is inherently imprecise and should not be adopted.

Bloomgarden ZT, Inzucchi SE, Karnieli E, Le Roith D.

Diabetologia. 2008 Jul;51(7):1111-4. doi: 10.1007/s00125-008-1027-7. Epub 2008 May 1. Review.

PMID:
18449525
30.

Transcriptional regulation of the GLUT4 gene: from PPAR-gamma and FOXO1 to FFA and inflammation.

Armoni M, Harel C, Karnieli E.

Trends Endocrinol Metab. 2007 Apr;18(3):100-7. Epub 2007 Feb 20.

PMID:
17317207
31.

Adult rat liver cells transdifferentiated with lentiviral IPF1 vectors reverse diabetes in mice: an ex vivo gene therapy approach.

Fodor A, Harel C, Fodor L, Armoni M, Salmon P, Trono D, Karnieli E.

Diabetologia. 2007 Jan;50(1):121-30. Epub 2006 Nov 28.

PMID:
17131142
32.

FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity.

Armoni M, Harel C, Karni S, Chen H, Bar-Yoseph F, Ver MR, Quon MJ, Karnieli E.

J Biol Chem. 2006 Jul 21;281(29):19881-91. Epub 2006 May 2.

33.

Inhibin B in men with severe obesity and after weight reduction following gastroplasty.

Globerman H, Shen-Orr Z, Karnieli E, Aloni Y, Charuzi I.

Endocr Res. 2005;31(1):17-26.

PMID:
16238188
34.

Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements.

Armoni M, Harel C, Bar-Yoseph F, Milo S, Karnieli E.

J Biol Chem. 2005 Oct 14;280(41):34786-95. Epub 2005 Aug 10.

35.

The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression.

Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E.

Cancer Res. 2004 Apr 1;64(7):2627-33.

36.

A model of the willingness to use telemedicine for routine and specialized care.

Werner P, Karnieli E.

J Telemed Telecare. 2003;9(5):264-72.

PMID:
14599329
37.

Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.

Armoni M, Kritz N, Harel C, Bar-Yoseph F, Chen H, Quon MJ, Karnieli E.

J Biol Chem. 2003 Aug 15;278(33):30614-23. Epub 2003 May 29.

38.

Plasma endothelin levels as a function of coronary artery manipulation during balloon angioplasty and high-speed rotational atherectomy.

Avizohar O, Karnieli E, Shen-Orr ZA, Rappaport B, Beyar R.

Int J Cardiovasc Intervent. 1998;1(2):93-98.

PMID:
12623398
39.

PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.

Armoni M, Quon MJ, Maor G, Avigad S, Shapiro DN, Harel C, Esposito D, Goshen Y, Yaniv I, Karnieli E.

J Clin Endocrinol Metab. 2002 Nov;87(11):5312-24.

PMID:
12414908
41.

Gynecomastia in a patient with celiac disease.

Globerman H, Suissa A, Karnieli E.

J Pediatr Endocrinol Metab. 2002 Jan;15(1):103-4. No abstract available.

PMID:
11822574
42.

The effect of acute insulin-like growth factor-II administration on glucose metabolism in the rat.

Burvin R, LeRoith D, Harel H, Zloczower M, Marbach M, Karnieli E.

Growth Horm IGF Res. 1998 Jun;8(3):205-10.

PMID:
10984308
43.

Analysis of the peroxisome proliferator activated receptor gamma (PPARgamma) gene in HAIRAN syndrome with obesity.

Globerman H, Zauberman Y, Makarov T, Beamer BA, Yen CJ, Shuldiner AR, Harel C, Karnieli E.

Clin Endocrinol (Oxf). 2000 Apr;52(4):479-85.

PMID:
10762291
44.

L-Glutamic acid gamma-monohydroxamate. A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo.

Goldwaser I, Li J, Gershonov E, Armoni M, Karnieli E, Fridkin M, Shechter Y.

J Biol Chem. 1999 Sep 10;274(37):26617-24.

47.

Double-vein jugular/inferior vena cava clamp technique for long-term in vivo studies in rats.

Burvin R, Zloczower M, Karnieli E.

Physiol Behav. 1998 Feb 15;63(4):511-5.

PMID:
9523892
48.

Repeated BCG vaccination is more effective than a single dose in preventing diabetes in non-obese diabetic (NOD) mice.

Shehadeh N, Etzioni A, Cahana A, Teninboum G, Gorodetsky B, Barzilai D, Karnieli E.

Isr J Med Sci. 1997 Nov;33(11):711-5.

PMID:
9434805
49.

The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein.

Karnieli E, Werner H, Rauscher FJ 3rd, Benjamin LE, LeRoith D.

J Biol Chem. 1996 Aug 9;271(32):19304-9.

50.

Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.

Werner H, Karnieli E, Rauscher FJ, LeRoith D.

Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8318-23.

Supplemental Content

Loading ...
Support Center